Table 1 Comparison the clinical and laboratory markers at glimepiride treatment and repaglinide treatment

Number (male)

9 (7)

9 (7)

-

Age (years)

68.0 ± 6.5

-

-

Duration (years)

18.3 ± 12.8

-

-

Body weight (kg)

64.3 ± 12.7

64.2 ± 12.3

0.86

Body mass index (kg/m²)

24.7 ± 3.7

24.7 ± 3.7

0.91

Dose (mg)

1.0 ± 0.4

0.75 ± 0.32

-

sBP (mmHg)

132.6 ± 4.2

126.2 ± 3.8

0.42

dBP (mmHg)

74.6 ± 4.0

70.6 ± 3.8

0.47

HbA1c (%)

7.0 ± 0.2

7.0 ± 0.2

0.62

FBS (mmol/L)

7.8 ± 1.9

7.7 ± 1.5

0.78

GA (%)

17.2 ± 1.7

17.3 ± 1.3

0.84

1,5-AG(mg/ml)

7.1 ± 3.3

7.1 ± 3.6

0.96

IRI (mU/ml)

6.0 ± 2.6

5.2 ± 3.6

0.41

s-CPR(mg/dl)

2.3 ± 1.9

1.6 ± 0.7

0.17

HOMA-IR

2.4 ± 1.7

2.1 ± 1.1

0.17

HOMA-β

33.7 ± 16.3

30.9 ± 15.8

0.15